New York, June 2, 2026, 08:07 (EDT)
IceCure Medical Ltd shares slipped in early U.S. pre-market trading on Tuesday, leaving the Nasdaq-listed medical device maker near 20 cents and still well below the exchange’s $1 minimum bid threshold. The stock last traded at $0.2011, down 1.9 cents, or about 8.6%, from its previous close.
That is why the move matters now. IceCure said in May it received a second 180-day period, until Nov. 9, 2026, to regain compliance with Nasdaq’s minimum bid price rule. The company said it would need its closing bid price — the price buyers are willing to pay — to stay at or above $1 for at least 10 straight business days, and said a reverse split, which consolidates shares to lift the per-share price, remained one possible step.
The U.S. market was not shut for a holiday. At the dateline time, Nasdaq was still in pre-market trading, the session before regular trading begins; Nasdaq lists regular hours as 9:30 a.m. to 4 p.m. Eastern time, with pre-market trading from 4 a.m. to 9:30 a.m.
IceCure had no newer item on its investor news page than a May 19 clinical update by early Tuesday. That left investors looking at the tape, the Nasdaq deadline and the company’s next commercial markers rather than a fresh company announcement.
The bull case still rests on adoption of ProSense, IceCure’s liquid-nitrogen cryoablation system. Cryoablation means freezing tissue to destroy tumors. In May, IceCure said first-quarter revenue rose 26% to $911,000, with North America revenue up 84% and U.S. revenue up 31%; Chief Executive Eyal Shamir said the company was “highly encouraged” by U.S. momentum after Food and Drug Administration clearance. PR Newswire
Clinical data are part of that pitch. IceCure said data presented around the European Conference on Interventional Oncology showed an 89.4% recurrence-free rate in kidney tumors of 3 centimeters or smaller after a median follow-up of four years. Shamir called the conference a “significant milestone” and pointed to “growing global momentum and commercial interest.” PR Newswire
The field is not empty. Boston Scientific markets its Visual ICE cryoablation system for minimally invasive tissue destruction, while AngioDynamics sells NanoKnife, which uses electrical pulses rather than freezing to target tumors. For IceCure, the market comparison matters less on Tuesday than the harder question of whether it can turn FDA clearance and clinical data into repeat U.S. sales.
The broader tape was not giving small health-care names much of a cushion. Reuters reported U.S. stock futures were mixed to lower before the open after the S&P 500 and Nasdaq posted an eighth straight advance and fresh record highs on Monday, with Nasdaq futures roughly flat while Dow and S&P 500 futures fell.
But the downside case is plain. A reverse split could solve the bid-price problem without fixing demand for the stock, and commercial adoption could take longer than investors expect. IceCure reported a first-quarter net loss of $4.27 million and cash of $8.12 million at March 31, while its own risk language pointed to funding needs, regulatory developments, sales execution and regional instability tied to Israel.
The next test is less dramatic than the product story: hold the listing, show orders, and keep cash from becoming the main story. Until the stock moves closer to $1, IceCure trades as much like a Nasdaq-compliance deadline as a medical-device growth bet.
